Enveric Biosciences Inc是一家处于早期发展阶段的生物科学公司。该公司正在利用临床发现平台开发下一代心理健康和肿瘤治疗,使迷幻药衍生的分子用于大脑,合成大麻素用于身体。为了符合美国联邦法规,该公司正在开发其候选产品,重点是从非大麻植物源中提取的大麻素,以及不含四氢大麻素(THC)的合成材料。其候选产品包括EV104、EVM-101、EVM-201、EVM-301、EV102和EV101。EV104包括坎那比妥(CBD)和塞来昔布结合物。EVM-101是第一代迷幻药,是一种赛洛西宾口服制剂。EVM-201是第二代迷幻剂资产,是裸头草辛的前药。EVM-301是第三代迷幻药。EV102是一种大麻素面霜,用于局部皮肤应用。EV101是一种大麻素加化疗的联合疗法。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Michael D. Webb | Independent Chairman of the Board | 2022 | 67 |
| Joseph Edward Tucker | CEO & Director | 2021 | 57 |
| George A. Kegler | Independent Non-Employee Director | 2020 | 70 |
| Maurizio Fava | Chairman of Scientific Advisory Board | 2022 | - |
| Frank Pasqualone | Independent Director | 2022 | 70 |
| Marcus Schabacker | Independent Non-Employee Director | 2020 | 62 |
| Stephen M. Stahl | Member of Scientific Advisory Board | 2022 | - |
| Sheila DeWitt | Independent Director | 2024 | 65 |
| John H. Krystal | Member of Scientific Advisory Board | 2022 | - |
| Michael B. Liebowitz | Member of Scientific Advisory Board | 2022 | - |